Piracetam for reducing the incidence of painful sickle cell disease crises

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2007, Pages

  Al Hajeri, Amani A ^a   Fedorowicz, Z ^b   Omran, A ^b   Tadmouri, G O ^b  

^a Ministry of Health   (Bahrain)

^b NONE

Author keywords

Adolescent; Anemia, sicklecell complications; *drug therapy ; Antisickling agents *therapeutic use ; Child; Child, preschool; Humans; Pain *drug therapy ; Piracetam *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

PIRACETAM; PLACEBO;

ACUTE CHEST SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA SYNTHESIS; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; INFECTION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SICKLE CELL ANEMIA; STROKE;

EID: 44949118529     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006111.pub2     Document Type: Review

References (33)

1. Alvim 2005 {published data only} Alvim RC, Viana MB, Pires MA, Franklin HM, Paula MJ, Brito AC, et al.Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. Acta Haematologica 2005;113(4):228-33.
2. El-Hazmi 1998 {published data only} *El-Hazmi M, Al-Fawaz I, Warsy A, Opawoye A, Taleb H, Howsawi Z, et al.Piracetam for the treatment of sickle cell disease in children - a double blind test. Saudi Medical Journal 1998;19(1):22-7.
3. El-Hazmi MA, Warsy AS, Al-Fawaz I, Farid M, Refai S, Opawoye AO, et al.Piracetam in the treatment of sickle cell disease [abstract]. The National Sickle Cell Disease Program Annual Meeting Conference Proceedings; 1995 March. 1995:162.
4. El-Hazmi MA, Warsy AS, Al-Fawaz I, Opawoye AO, Abu Taleb H, Howsawi Z, et al.Piracetam is useful in the treatment of children with sickle cell disease. Acta Haematologica 1996;96(4):221-6.
5. Mikati 1983 {published data only} Mikati MA, Solh HM, Deryan DE, Sahli IF, Dabbous IA. A preliminary report on piracetam in sickle cell anemia: a double-blind crossover clinical trial and effects on erythrocyte survival. The King Faisal Specialist Hospital Medical Journal 1983;3(4):233-6.
6. De Araujo 1977 De Araujo JT, Nero GS. Piracetam and acetamide in sickle-cell disease. Lancet 1977;2(8034):411.
7. De Melo 1976 DeMelo GO. Piracetamin sickle cell anaemia. Lancet 1976;2(7995):1139.
8. Franklin 1980 Franklin IM. Piracetam in sickle cell disease. Lancet 1980;1(8143):767.
9. Gini 1987 Gini EK, Sonnet J. Use of piracetam improves sickle cell deformability in vivo. Journal of Clinical Pathology 1987;40(1):99-102.
10. Sonnet 1985 Sonnet J, Gini EK, Cornu G. Trial prevention of vaso-occlusive crises in homozygote in sickle cell anemia using piracetam [Essai de prevention des crises vaso-occlusives de la drepanocytose homozygote par le piracetam]. Annales de la Société belge de médecine tropicale 1985;65(1):77-84.
11. Al-Arrayed 1995 Al-Arrayed SS, Haites N. Features of sickle-cell disease in Bahrain. Eastern Mediterranean Health Journal 1995;1(1):112-9.
12. Asakura 1981 Asakura T, Ohnishi ST, Adachi K, Ozguc M, Hashimoto K, Devlin MT, et al.Effect of piracetam on sickle erythrocytes and sickle hemoglobin. Biochimica et Biophysica Acta 1981;668(3):397-405.
13. Balkaran 1992 Balkaran B, Char G, Morris JS, Serjeant BE, Serjeant GR. Stroke in a cohort study of patients with homozygous sickle cell disease. Journal of Pediatrics 1992;120(3):360-6.
14. Brozovic 1987 Brozovic M, Davies SC. Management of sickle cell disease. Postgraduate Medical Journal 1987;63(742):605-9.
15. Castro 1994 Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al.The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood 1994;84(2):643-9.
16. Davies 1997 Davies SC, Oni L. The management of patients with sickle cell disease. BMJ 1997;315(7109):656-60.
17. Davies 2004 Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews 2004, Issue 1.Art. No.: CD003885. DOI:10.1002/14651858. CD003885.pub2.
18. de Araujo 1977 de Araujo JT, Nero GS. Piracetamand acetamide in sickle-cell disease. Lancet 1977;2(8034):411.
19. El-Hazmi 1990 El-Hazmi MA, Bahakim HM, al-Swailem AM, Warsy AS. The features of sickle cell disease in Saudi children. Journal of Tropical Pediatrics 1990;36(4):148-55.
20. El-Hazmi 1992 El-Hazmi MAF, Warsy AS, Al Momen AK, Harakati M. Hydroxyurea for the treatment of sickle cell disease. Acta Haematologica 1992;88(4):170-4.
21. Elbourne 2002 Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
22. Goldberg 1958 Goldberg CAJ. A new method for starch gel electrophoresis with special reference to the determination of hemoglobin A2. Clinical Chemistry 1958;4:484.
23. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd; 2005, Issue 3 2005.
24. Jones 2001 Jones AP, Davies S, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2.Art. No.: CD002202. DOI:10.1002/14651858.CD002202.
25. Knight 1995 Knight S, Singhal A, Thomads P, Serjeant GR. Factors associated with lowered intelligence in homozygous sickle cell disease. Archives of Disease in Childhood 1995;73(4):316-20.
26. Moriau 1993 Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung 1993;43(2):110-8.
27. NIH 2002 National Heart, Lung and Blood Institute, National Institutes of Health. The Management of Sickle Cell Disease. NIH Publ No 02-2117 2002.
28. RevMan 2005 The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Oxford, England: The Cochrane Collaboration, 2005.
29. Serjeant 1994 Serjeant GR. The geography of sickle-cell disease: opportunity for understanding its diversity. Annals of Saudi Medicine 1994;14:237-46.
30. Serjeant 2001 Serjeant GR, Serjeant BE. Sickle Cell Disease. 3rd Edition. Oxford: Oxford University Press, 2001.
31. Topley 1981 Topley JM, Rogers DW, Stevens MC, Serjeant GR. Acute splenic sequestration and hypersplenism in the 5 years of life in homozygous sickle cell disease. Archives of Disease in Childhood 1981;56(10):765-9.
32. Vernon 1991 Vernon MW, Sorkin EM. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs and Aging 1991;1(1):17-35.
33. WHO 2006 World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. www.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 15 February 2006).